Table 1.
Demographic and clinicopathologic characteristics.
| Total | PLMR | ILMR | BILMR | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 197 | Low (133) | High (64) | P value | Low (94) | High (103) | P value | Low (118) | High (79) | P value | |
| Sex | 0.148 | 0.026 | 0.575 | |||||||
| Female | 27 (13.7%) | 22 (11.2%) | 5 (2.5%) | 7 (3.6%) | 20 (10.2%) | 18 (9.1%) | 9 (4.6%) | |||
| Male | 170 (86.3%) | 111 (56.3%) | 59 (29.9%) | 87 (44.2%) | 83 (42.1%) | 100 (50.8%) | 70 (35.5%) | |||
| Age | 64.17 | 62.44 | 67.77 | 0.001 | 66.46 | 62.08 | 0.005 | 64.13 | 64.23 | 0.950 |
| ±11.05 | ± 11.2 | ± 9.97 | ± 10.9 | ± 10.87 | ± 11.04 | ± 11.2 | ||||
| BMI | 23.65 | 23.63 | 23.68 | 0.925 | 22.7 | 24.51 | < 0.001 | 23.15 | 24.39 | 0.005 |
| ±3.04 | ± 3.01 | ± 3.14 | ± 2.87 | ± 2.95 | ± 2.83 | ± 3.22 | ||||
| Smoker | 0.092 | 0.682 | 0.162 | |||||||
| No | 140 (71.1%) | 89 (45.2%) | 51 (25.9%) | 65 (33%) | 75 (38.1%) | 79 (40.1%) | 61 (31%) | |||
| Yes | 57 (28.9%) | 44 (22.3%) | 13 (6.6%) | 29 (14.7%) | 28 (14.2%) | 39 (19.8%) | 18 (9.1%) | |||
| Gross hematuria | 0.358 | 0.390 | 0.294 | |||||||
| No | 46 (23.4%) | 28 (14.2%) | 18 (9.1%) | 25 (12.7%) | 21 (10.7%) | 24 (12.2%) | 22 (11.2%) | |||
| Yes | 151 (76.6%) | 105 (53.3%) | 46 (23.4%) | 69 (35%) | 82 (41.6%) | 94 (47.7%) | 57 (28.9%) | |||
| Hypertension | 0.182 | 0.682 | 1.000 | |||||||
| No | 140 (71.1%) | 99 (50.3%) | 41 (20.8%) | 65 (33%) | 75 (38.1%) | 84 (42.6%) | 56 (28.4%) | |||
| Yes | 57 (28.9%) | 34 (17.3%) | 23 (11.7%) | 29 (14.7%) | 28 (14.2%) | 34 (17.3%) | 23 (11.7%) | |||
| Diabetes | 0.529 | 0.854 | 1.000 | |||||||
| No | 172 (87.3%) | 118 (59.9%) | 54 (27.4%) | 83 (42.1%) | 89 (45.2%) | 103 (52.3%) | 69 (35%) | |||
| Yes | 25 (12.7%) | 15 (7.6%) | 10 (5.1%) | 11 (5.6%) | 14 (7.1%) | 15 (7.6%) | 10 (5.1%) | |||
| Tumor size a | 0.942 | 0.045 | 0.321 | |||||||
| <=3cm | 110 (55.8%) | 75 (38.1%) | 35 (17.8%) | 45 (22.8%) | 65 (33%) | 62 (31.5%) | 48 (24.4%) | |||
| >3cm | 87 (44.2%) | 58 (29.4%) | 29 (14.7%) | 49 (24.9%) | 38 (19.3%) | 56 (28.4%) | 31 (15.7%) | |||
| Tumor number | 0.632 | 0.466 | 0.240 | |||||||
| Single | 86 (43.7%) | 56 (28.4%) | 30 (15.2%) | 38 (19.3%) | 48 (24.4%) | 47 (23.9%) | 39 (19.8%) | |||
| Multiple | 111 (56.3%) | 77 (39.1%) | 34 (17.3%) | 56 (28.4%) | 55 (27.9%) | 71 (36%) | 40 (20.3%) | |||
| WHO grade | 0.580 | 0.383 | 0.037 | |||||||
| Low | 55 (27.9%) | 35 (17.8%) | 20 (10.2%) | 23 (11.7%) | 32 (16.2%) | 26 (13.2%) | 29 (14.7%) | |||
| High | 142 (72.1%) | 98 (49.7%) | 44 (22.3%) | 71 (36%) | 71 (36%) | 92 (46.7%) | 50 (25.4%) | |||
| CIS | 0.569 | 0.574 | 0.868 | |||||||
| No | 182 (92.4%) | 25 (12.7%) | 15 (7.6%) | 17 (8.6%) | 23 (11.7%) | 23 (11.7%) | 17 (8.6%) | |||
| Yes | 15 (7.6%) | 108 (54.8%) | 49 (24.9%) | 77 (39.1%) | 80 (40.6%) | 95 (48.2%) | 62 (31.5%) | |||
| T stage | 0.570 | 1.000 | 1.000 | |||||||
| Ta | 40 (20.3%) | 124 (62.9%) | 58 (29.4%) | 87 (44.2%) | 95 (48.2%) | 109 (55.3%) | 73 (37.1%) | |||
| T1 | 157 (79.7%) | 9 (4.6%) | 6 (3%) | 7 (3.6%) | 8 (4.1%) | 9 (4.6%) | 6 (3%) | |||
| Histology | 0.981 | 0.645 | 0.975 | |||||||
| No HV | 171 (86.8%) | 116 (58.9%) | 55 (27.9%) | 80 (40.6%) | 91 (46.2%) | 103 (52.3%) | 68 (34.5%) | |||
| HV | 26 (13.2%) | 17 (8.6%) | 9 (4.6%) | 14 (7.1%) | 12 (6.1%) | 15 (7.6%) | 11 (5.6%) | |||
| Recurrence | 0.006 | 0.002 | 0.448 | |||||||
| No | 112 (56.9%) | 85 (43.1%) | 27 (13.7%) | 42 (21.3%) | 70 (35.5%) | 64 (32.5%) | 48 (24.4%) | |||
| Yes | 85 (43.1%) | 48 (24.4%) | 37 (18.8%) | 52 (26.4%) | 33 (16.8%) | 54 (27.4%) | 31 (15.7%) | |||
| Progression | 0.056 | 0.009 | 0.408 | |||||||
| No | 142 (72.1%) | 102 (51.8%) | 40 (20.3%) | 59 (29.9%) | 83 (42.1%) | 82 (41.6%) | 60 (30.5%) | |||
| Yes | 55 (27.9%) | 31 (15.7%) | 24 (12.2%) | 35 (17.8%) | 20 (10.2%) | 36 (18.3%) | 19 (9.6%) | |||
a
: For multiple tumors, the diameter of the largest tumor was regarded as tumor size. BMI, Body mass index; WHO, World Health Organization; CIS, Carcinoma in situ; HV, Histological variant; PLMR, Preoperative lymphocyte-to-monocyte ratio; ILMP, Lymphocyte-to-monocyte ratio during induction; PILMR, Preoperative dividing by induction lymphocyte -to- monocyte ratio; n, number.